Category Resources

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—November 2024 Newsletter

mRNA for Antibody Manufacturing In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into…

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—October 2024 Newsletter

Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and…

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—September 2024 Newsletter

Speaking of Mol Bio Podcast In the latest episode (Season 2, Episode 8) of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The…

Speaking of Mol Bio Podcast: S2 E8 Therapeutic nucleic acids—A CDMO’s view on mRNA

CDMO Insights on Therapeutic mRNA

In the latest episode of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The COVID pandemic has brought mRNA into the spotlight, showcasing…

Absolute Gene-ius Podcast: S2 E9 Helping democratize access and use of mRNA technology

Democratizing mRNA Technology

Podcast Abstract: In the latest episode of the Absolute Gene-ius Podcast, hosts Christina Bouwens and Dr. Christian Cobaugh, CEO of Vernal Biosciences, dive into the evolving landscape of mRNA technology and democratizing mRNA technology. With a mission to enhance access…

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—August 2024 Newsletter

Rapid Single Epitope mRNA Production This article presents a synthetic DNA template (SDT) process for manufacturing single epitope mRNA, offering a flexible, cost-efficient, and rapid alternative to traditional plasmid DNA templates (PDT). Read the article to explore what can be…

Benefits of Partnering with a US-Based CDMO

The mRNA Monthly—July 2024 Newsletter

Phase 2b Autoimmune CAR-T Win Congratulations to Cartesian Therapeutics on their Phase 2b autoimmune CAR-T trial success—shifting the intensity of the cell therapy paradigm! This milestone is a testament to their innovation. It’s exciting to see mRNA as part of…